An Appraisal of Clinically Meaningful Outcomes Guidelines for Oncology Clinical Trials

JAMA Oncol. 2016 Sep 1;2(9):1238-40. doi: 10.1001/jamaoncol.2016.0931.

Authors

Hemanth Kumar¹, Tito Fojo², Sham Mailankody³

Affiliations

¹ Department of Medical Oncology, Kasturba Medical College, Manglaore, India.
² Division of Hematology and Oncology, Columbia University Medical Center, New York, New York.
³ Myeloma Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.

No abstract available

MeSH terms

Antineoplastic Agents / therapeutic use*
Clinical Trials as Topic
Disease-Free Survival
Drug Approval
Guidelines as Topic*
Humans
Medical Oncology
Neoplasms / drug therapy*
Outcome Assessment, Health Care
Societies, Medical
Survival Rate
United States
United States Food and Drug Administration

Substances

Antineoplastic Agents

Grants and funding

P30 CA008748/CA/NCI NIH HHS/United States